DLA Piper advises on the acquisition of Austrian biotech company Panoptes by EyeGate

DLA Piper has advised Austrian biotech company Panoptes Pharma (Panoptes) on its acquisition by EyeGate Pharmaceuticals (EyeGate), a clinical stage company focused on developing products for treating disorders of the eye. The transaction was closed on 20 December 2020.

EyeGate acquired 100% of the shares in Panoptes. Co-founders Dr. Franz Obermayr and Dr. Stefan Sperl, as well as the institutional and strategic investors, sold their stake by way of a share swap and now hold an interest in EyeGate. Under the terms of the agreement, Panoptes becomes a wholly owned subsidiary of EyeGate, and its co-founders become part of the EyeGate management team.

DLA Piper advised Panoptes as well as its co-founders Dr. Franz Obermayr and Dr. Stefan Sperl and other shareholders. The team was led by Vienna-based Corporate partner Christoph Mager, counsel Johanna Höltl and senior associate Christian Knauder.

Commenting, DLA Piper’s partner Christoph Mager, said: “We are very pleased to have advised Panoptes Pharma on this strategically important transaction, which is testament to the Panoptes team’s success in developing their novel and highly innovative products.”

Based in Vienna, Panoptes Pharma Gmbh is a privatively held clinical stage biotech company focused on developing a novel proprietary small molecule for the treatment of severe eye diseases with a high unmet medical need.

EyeGate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company focused on developing and commercializing products for treatingdiseases and disorders of the eye. The company is listed on the Nasdaq and is headquartered in Waltham, Massachusetts.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.